Category: cost effectiveness

The Promise of Population-based Genomic Screening for Selected Hereditary Conditions: Contributions of Cost-Effectiveness Analysis

individuals connected with DNA and dollar bills in the background

It is estimated that 3 million people in the United States carry pathogenic variants that increase their risks for heart disease and cancer. If people with such variants are identified, medical interventions are available to significantly reduce morbidity and mortality. However, existing recommendations tend to emphasize family-based or ethnic-specific criteria to determine at-risk individuals for Read More >

Posted on by Nandana D. Rao, Lu Shi, Muin J. Khoury, Office of Genomics and Precision Public Health, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia1 Comment
Categories genomics, Population screening
Tags ,

Cost-effectiveness of Pharmacogenomic Testing: How to Measure the Value of Having the Right Dose of the Right Drug for the Right Patient

a stethoscope with money, pills with DNA inside them, a crowd and a few people in the inner circle being target, and a doctor talking to a patient in a hospital bed

A recent systematic review that assessed the cost-effectiveness of pharmacogenetic testing for drugs with existing guidelines concluded that most studies favored pharmacogenomic testing. The significance of this conclusion must be interpreted with caution and in the context of study factors, such as funding sources, geography, cohort, and the cost-effectiveness comparisons being made. Pharmacogenomics (PGx) combines Read More >

Posted on by Lu Shi, Zhuo Chen, W. David Dotson, Katherine Kolor, Scott Grosse, Muin J. Khoury {Office of Genomics and Precision Public Health, National Canter on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia}
Categories genomics, pharmacogenomics
Tags ,